New five-year data on Susvimo – a refillable implant that delivers continuous ranibizumab to the eye – has shown the treatment’s ability to maintain vision and retinal drying over a long period of time for people with neovascular age-related macular degeneration (nAMD).
Drug manufacturer Roche revealed the new, five-year efficacy, safety and durability data from the Phase 3 Portal study findings on 1 August 2025. It’s a long-term extension of the Phase 3 Archway study, of Susvimo.
Results show that Susvimo’s “immediate and predictable durability was sustained over five years”, with approximately 95% of people receiving treatment every six months requiring no supplemental treatment before each refill. The data was presented at the American Society of Retina Specialists (ASRS) 2025 Annual Meeting in Long Beach, California, US.
The treatment represents a new alternative to the standard of care – frequent intravitreal injections. Susvimo provides continuous delivery of a customised formulation of ranibizumab via the Port Delivery Platform. The platform is a refillable implant surgically inserted into the eye during a one-time, outpatient procedure, which introduces medicine directly into the eye.
“These long-term results reinforce Susvimo’s ability to maintain vision and retinal drying over a long period of time for people with nAMD, the leading cause of vision loss in people over age 60,” said Dr Levi Garraway, Roche’s chief medical officer and head of global product development.
“These robust data reinforce our confidence in Susvimo’s unique therapeutic approach, providing an effective alternative to regular eye injections while preserving vision in a sustained manner.”
Study investigator Dr John Kitchens, from Retina Associates of Kentucky and who presented the data at ASRS, said people with nAMD often experienced suboptimal outcomes with real-world anti-VEGF treatment, largely due to the frequency of injections.
“Continuous delivery of treatment with Susvimo may preserve vision in patients with nAMD for longer in real-world clinical use than intravitreal injections,” he said.
In the Portal study (n = 352), people originally treated with Susvimo in Archway continued to receive Susvimo refills every six months (Susvimo cohort; n = 220), while those originally treated with monthly intravitreal (IVT) ranibizumab injections in Archway received Susvimo and then refills every six months (IVT-Susvimo cohort; n = 132).
Five-year results showed consistent and sustained disease control and retinal drying in a population who entered Archway with vision at or near peak levels after receiving an average of five intravitreal injections per standard of care.
In the Susvimo cohort, best-corrected visual acuity (BCVA) was 74.4 letters at baseline and 67.6 letters at five years. In the IVT-Susvimo cohort, BCVA was 76.3 letters at baseline and 68.6 at 5 years. Half of all patients had better than 20/40 vision at five years (Snellen visual acuity test). Average central subfield thickness (CST) remained stable, with a 1.4 (95% CI: -13.1, 11.1) µm reduction from baseline in the Susvimo cohort, and a 4.2 (95% CI: -25.7, 5.0) µm reduction in the IVT-Susvimo cohort.
The cohort of people who entered the Portal study from Archway is the largest cohort of people with nAMD to be followed prospectively and continuously for five years in a clinical study.
More reading
Anti-VEGF remains most expensive PBS drug
Port delivery system for neovascular AMD – A/Prof Anthony Kwan
FDA approves Susvimo continuous drug delivery implant for AMD
